Page last updated: 2024-08-24

gemcitabine and xct790

gemcitabine has been researched along with xct790 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Cai, C; Dong, P; Gong, W; Li, ML; Liang, HB; Liu, SL; Wu, XS; Wu, ZY; Yang, ZY; Zheng, L	1

Other Studies

1 other study(ies) available for gemcitabine and xct790

Article	Year
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. International journal of medical sciences, 2022, Volume: 19, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; ERRalpha Estrogen-Related Receptor; Gemcitabine; Humans; MAP Kinase Signaling System; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Thiazoles; Xenograft Model Antitumor Assays	2022

Article

Year

Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.

International journal of medical sciences, 2022, Volume: 19, Issue:2

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; ERRalpha Estrogen-Related Receptor; Gemcitabine; Humans; MAP Kinase Signaling System; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Thiazoles; Xenograft Model Antitumor Assays

2022